Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.71 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.68 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.68 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26079448 | 0.84 | MTNR1A (0.68) | MTNR1AMTNR1BHDAC6 | |
| SCHEMBL9215928 | 0.84 | SPR (0.67) | SPRMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL5632567 | 0.83 | SPR (0.66) | SPRMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL934634 | 0.83 | CYP3A4 (0.53) | SPRMTNR1AMTNR1B | |
| SCHEMBL19002545 | 0.83 | SPR (0.66) | SPRMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL12720969 | 0.83 | SPR (1.00) | SPRMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL21776338 | 0.83 | SPR (0.66) | SPRMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL31173308 | 0.83 | MTNR1A (0.67) | MTNR1AMTNR1B | |
| SCHEMBL14241863 | 0.83 | MTNR1A (0.67) | SPRMTNR1AMTNR1B | |
| SCHEMBL14241870 | 0.83 | ALDH1A1 (0.71) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | SPR 3639/4885MTNR1A 1704/4885MTNR1B 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.